Evidence map›Paper›PMID 26840126›Full record

ArticlePloS one2016

A Temperature Sensitive Variant of p53 Drives p53-Dependent MicroRNA Expression without Evidence of Widespread Post-Transcriptional Gene Silencing.

Miguel A Cabrita, Erin J Vanzyl, Jeff D Hamill, Elysia Pan, Kristen A Marcellus, Victoria J Tolls, Rhea C Alonzi, Alyssa Pastic, Teeghan M E Rambo, Hadil Sayed and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Cells · 2022
    Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Miguel A CabritaCentre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa ON.
Erin J VanzylDepartment of Biology, Carleton University, Ottawa, ON.
Jeff D HamillCentre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa ON.
Elysia PanCentre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa ON.
Kristen A MarcellusCentre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa ON.
Victoria J TollsDepartment of Biology, Carleton University, Ottawa, ON.
Rhea C AlonziInstitute for Biochemistry, Carleton University, Ottawa, ON.
Alyssa PasticDepartment of Biology, Carleton University, Ottawa, ON.
Teeghan M E RamboDepartment of Biology, Carleton University, Ottawa, ON.
Hadil SayedDepartment of Biology, Carleton University, Ottawa, ON.
Bruce C McKayCentre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa ON.
Carleton University · CAOttawa Hospital · CAOttawa Hospital Research Institute

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

The p53 tumour suppressor is a transcription factor that can regulate the expression of numerous genes including many encoding proteins and microRNAs (miRNAs). The predominant outcomes of a typical p53 response are the initiation of apoptotic cascades and the activation of cell cycle checkpoints. HT29-tsp53 cells express a temperature sensitive variant of p53 and in the absence of exogenous DNA damage, these cells preferentially undergo G1 phase cell cycle arrest at the permissive temperature that correlates with increased expression of the cyclin-dependent kinase inhibitor p21WAF1. Recent evidence also suggests that a variety of miRNAs can induce G1 arrest by inhibiting the expression of proteins like CDK4 and CDK6. Here we used oligonucleotide microarrays to identify p53-regulated miRNAs that are induced in these cells undergoing G1 arrest. At the permissive temperature, the expression of several miRNAs was increased through a combination of either transcriptional or post-transcriptional regulation. In particular, miR-34a-5p, miR-143-3p and miR-145-5p were strongly induced and they reached levels comparable to that of reference miRNAs (miR-191 and miR-103). Importantly, miR-34a-5p and miR-145-5p are known to silence the Cdk4 and/or Cdk6 G1 cyclin-dependent kinases (cdks). Surprisingly, there was no p53-dependent decrease in the expression of either of these G1 cdks. To search for other potential targets of p53-regulated miRNAs, p53-downregulated mRNAs were identified through parallel microarray analysis of mRNA expression. Once again, there was no clear effect of p53 on the repression of mRNAs under these conditions despite a remarkable increase in p53-induced mRNA expression. Therefore, despite a strong p53 transcriptional response, there was no clear evidence that p53-responsive miRNA contributed to gene silencing. Taken together, the changes in cell cycle distribution in this cell line at the permissive temperature is likely attributable to transcriptional upregulation of the CDKN1A mRNA and p21WAF1 protein and not to the down regulation of CDK4 or CDK6 by p53-regulated miRNAs.

Indexed as

G1 Phase Cell Cycle CheckpointsGene Expression Regulation, NeoplasticGene SilencingCell Line, TumorCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Cyclin-Dependent Kinase Inhibitor p21HumansMicroRNAsRNA, NeoplasmTumor Suppressor Protein p53CDK4 protein, humanCDK6 protein, humanCDKN1A protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Cyclin-Dependent Kinase Inhibitor p21MicroRNAsRNA, NeoplasmTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID26840126
PMCPMC4739602
OpenAlexW2258709019

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.